Ranked: Top-Performing Enterprise AI Stocks of 2025 (So Far)

The Category-Leading Brands Investors Can't Ignore in 2025

The 20 Most Valuable Drink Stocks Ranked by Market Cap

Top Rising Companies by Brand Value Growth in 2025

Charted: Risk vs Reward of the Top 20 High-Growth Platform Stocks

The World’s 20 Most Valuable Brands in 2025

Discover 4 Layers of Crypto Investing Opportunities

Stablecoins Go Mainstream: What Investors Should Know

Tutor Perini Stock (TPC): Financial Momentum and Growth Prospects

Tutor Perini crushed Q2 with a 315% EPS jump and record cash flow—setting the stage for more gains as high-margin projects ramp up.

Duolingo Stock (DUOL): AI and Music Learning Propel Performance

Duolingo just crushed Q2 expectations, sending shares soaring up to 20% as it leans hard into AI and dives into gamified music learning.

Cricut Stock (CRCT): Earnings Beat Yet Analyst Caution

Cricut (CRCT) beats Q2 earnings but faces analyst caution.

Champion Homes Stock (SKY): Strong Q1 Earnings Surge

Champion Homes (SKY) shines with Q1 FY26 results, positive growth, and strategic milestones boosting investor confidence.

Flywire Stock (FLYW): Strong Earnings and Growth Potential

Flywire's Q2 2025 revenue grew 27% to $131.9M while EBITDA surged to $16.6M, reflecting strong growth prospects in travel and strategic acquisitions.

Indivior Stock (INDV): Strong Earnings Boost Investor Confidence

Indivior exceeded Q2 2025 expectations, raising full-year forecasts, driven by strong Sublocade demand, boosting stock by ~21%.

CVS Health Stock (CVS): Strong Q2 Performance and Future Outlook

CVS Health showed strong Q2 2025 results, boosting EPS guidance and share price, driven by Aetna and pharmacy growth.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

Xylem Stock (XYL): Strong Earnings and Growth Outlook

Xylem reported strong Q2 2025 results, raising full-year guidance amid robust revenue growth.

Interface Stock (TILE): Impressive Q2 Leads to Growth

Interface’s Q2 2025 shows strong growth, with net sales up 8.3% year-over-year and adjusted EPS rising 50% to $0.60, prompting an increase in full-year revenue guidance to $1.37B–$1.39B.

Exact Sciences Stock (EXAS): Cologuard Plus Expansion Benefits

Exact Sciences broadens partnership with Humana, offering Cologuard Plus for 5.8 million members, enhancing access and driving growth.

Salesforce Stock (CRM): Major Investments in AI Solutions

Salesforce and ServiceNow invest $1.5 billion in Genesys, strengthening AI capabilities in customer service software.